Modulatory Potential of Cannabidiol on the Opioid-Induced Inflammatory Response
- 1 June 2021
- journal article
- research article
- Published by SAGE Publications in Cannabis & Cannabinoid Research
- Vol. 6 (3) , 211-220
Abstract
Opioids are effective analgesics; however, there are many negative consequences of chronic use. One important side effect of chronic opioid use is the continuous engagement of the immune response that can exacerbate chronic pain. The opioid, morphine, initiates a Toll-like receptor 4 (TLR4) signaling cascade that drives the activation of NOD-, LRR-, and pyrin domain-containing protein 3 (NLRP3) inflammasome proteins, resulting in cytokine production and effectively creating a positive feedback loop for continuous TLR4 activation. In addition to driving cytokine production, morphine drives changes in proinflammatory lipid signaling. The alteration of both cytokine and lipid signaling systems by morphine suggests that its chronic use leads to a pathological immune response that would benefit from targeted therapy. Engaging the endogenous cannabinoid system has shown therapeutic benefit, particularly regarding its anti-inflammatory and immunosuppressive effects. Promising preclinical and clinical investigations suggest that cannabidiol (CBD) is an effective adjuvant for treatment of symptoms of opioid use disorders; however, the mechanism through which CBD drives this outcome is unclear. One potential source of insight into this mechanism is in how CBD regulates immune regulators such as cytokines and lipid signaling systems, including endocannabinoids and related immune-responsive lipids. In this review, we outline the immune response to chronic opioid use as well as CBD in the context of a lipopolysaccharide-induced immune response and speculate on the mechanism of CBD as a modulator of chronic opioid-induced immune system dysregulation.Keywords
This publication has 57 references indexed in Scilit:
- Morphine activates neuroinflammation in a manner parallel to endotoxinProceedings of the National Academy of Sciences of the United States of America, 2012
- Differential transcriptional profiles mediated by exposure to the cannabinoids cannabidiol and Δ9‐tetrahydrocannabinol in BV‐2 microglial cellsBritish Journal of Pharmacology, 2012
- Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophreniaTranslational Psychiatry, 2012
- Molecular Mechanisms of Opioid Receptor-dependent Signaling and BehaviorAnesthesiology, 2011
- Inflammatory hyperalgesia induces essential bioactive lipid production in the spinal cordJournal of Neurochemistry, 2010
- Pattern Recognition Receptors and InflammationCell, 2010
- Cannabinoids Δ9-Tetrahydrocannabinol and Cannabidiol Differentially Inhibit the Lipopolysaccharide-activated NF-κB and Interferon-β/STAT Proinflammatory Pathways in BV-2 Microglial CellsJournal of Biological Chemistry, 2010
- AP-1 Activated by Toll-like Receptors Regulates Expression of IL-23 p19Journal of Biological Chemistry, 2009
- The orphan receptor GPR55 is a novel cannabinoid receptorBritish Journal of Pharmacology, 2007
- Chronic Morphine Modulates the Contents of the Endocannabinoid, 2-Arachidonoyl Glycerol, in Rat BrainNeuropsychopharmacology, 2002